{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:29:11Z","timestamp":1794011351162,"version":"4.8.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40265-024-01993-x","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T02:01:57Z","timestamp":1709604117000},"page":"257-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Adult-Onset Still\u2019s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9409-3329","authenticated-orcid":false,"given":"Sara","family":"Bindoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-9314","authenticated-orcid":false,"given":"Chiara","family":"Baggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-7174","authenticated-orcid":false,"given":"Paolo","family":"Sfriso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"1993_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","volume":"78","author":"P Sfriso","year":"2018","unstructured":"Sfriso P, Bindoli S, Galozzi P. Adult-Onset still\u2019s disease: molecular pathophysiology and therapeutic advances. Drugs. 2018;78:1187\u201395. https:\/\/doi.org\/10.1007\/s40265-018-0956-9.","journal-title":"Drugs"},{"key":"1993_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","volume":"13","author":"N Nirmala","year":"2015","unstructured":"Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol. 2015;13:50. https:\/\/doi.org\/10.1186\/s12969-015-0047-3.","journal-title":"Pediatr Rheumatol"},{"key":"1993_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-019-0053-z","volume":"3","author":"H Kudela","year":"2019","unstructured":"Kudela H, Drynda S, Lux A, et al. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still\u2019s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol. 2019;3:4. https:\/\/doi.org\/10.1186\/s41927-019-0053-z.","journal-title":"BMC Rheumatol"},{"key":"1993_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","volume":"25","author":"S Pay","year":"2006","unstructured":"Pay S, T\u00fcrk\u00e7apar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still\u2019s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639\u201344. https:\/\/doi.org\/10.1007\/s10067-005-0138-5.","journal-title":"Clin Rheumatol"},{"key":"1993_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100196","volume":"6","author":"S Li","year":"2023","unstructured":"Li S, Ying S, Bai J, et al. Clinical characteristics and outcome of elderly onset adult-onset Still\u2019s disease: a 10-year retrospective study. J Transl Autoimmun. 2023;6: 100196. https:\/\/doi.org\/10.1016\/j.jtauto.2023.100196.","journal-title":"J Transl Autoimmun"},{"key":"1993_CR6","doi-asserted-by":"publisher","first-page":"101632","DOI":"10.1016\/j.smim.2022.101632","volume":"58","author":"P Ruscitti","year":"2021","unstructured":"Ruscitti P, Berardicurti O, Giacomelli R, et al. The clinical heterogeneity of adult onset Still\u2019s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. Semin Immunol. 2021;58:101632. https:\/\/doi.org\/10.1016\/j.smim.2022.101632.","journal-title":"Semin Immunol"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1093\/rheumatology\/keaa904","volume":"60","author":"O Berardicurti","year":"2021","unstructured":"Berardicurti O, Conforti A, Iacono D, et al. Dissecting the clinical heterogeneity of adult-onset Still\u2019s disease: results from a multi-dimensional characterization and stratification. Rheumatology. 2021;60:4844\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa904.","journal-title":"Rheumatology"},{"key":"1993_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","volume":"70","author":"M Del Giudice","year":"2018","unstructured":"Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61\u201375. https:\/\/doi.org\/10.1016\/j.bbi.2018.02.013.","journal-title":"Brain Behav Immun"},{"key":"1993_CR9","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/jcm10235586","volume":"10","author":"M Delplanque","year":"2021","unstructured":"Delplanque M, Aouba A, Hirsch P, et al. USAID Associated with myeloid neoplasm and VEXAS syndrome: two differential diagnoses of suspected adult onset still\u2019s disease in elderly patients. J Clin Med. 2021;10:5586. https:\/\/doi.org\/10.3390\/jcm10235586.","journal-title":"J Clin Med"},{"key":"1993_CR10","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330."},{"key":"1993_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","volume":"81","author":"B Fautrel","year":"2002","unstructured":"Fautrel B, Zing E, Golmard J-L, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81:194\u2013200. https:\/\/doi.org\/10.1097\/00005792-200205000-00003.","journal-title":"Medicine (Baltimore)"},{"key":"1993_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10067-023-06509-8","volume":"42","author":"K Daghor-Abbaci","year":"2023","unstructured":"Daghor-Abbaci K, Ait Hamadouche N, Makhloufi CD, et al. Proposal of a new diagnostic algorithm for adult-onset Still\u2019s disease. Clin Rheumatol. 2023;42:1125\u201335. https:\/\/doi.org\/10.1007\/s10067-023-06509-8.","journal-title":"Clin Rheumatol"},{"key":"1993_CR13","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3899\/jrheum.100247","volume":"37","author":"M Rau","year":"2010","unstructured":"Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis. J Rheumatol. 2010;37:2369\u201376. https:\/\/doi.org\/10.3899\/jrheum.100247.","journal-title":"J Rheumatol"},{"key":"1993_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10067-022-06340-7","volume":"42","author":"D Zhu","year":"2023","unstructured":"Zhu D, Meng J, Jia J, et al. Performance of the modified systemic manifestation score for systemic juvenile idiopathic arthritis in adult-onset Still\u2019s disease. Clin Rheumatol. 2023;42:187\u201395. https:\/\/doi.org\/10.1007\/s10067-022-06340-7.","journal-title":"Clin Rheumatol"},{"key":"1993_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/art.1780241203","volume":"24","author":"R Terkeltaub","year":"1981","unstructured":"Terkeltaub R, Esdaile JM, D\u00e9cary F, et al. HLA\u2014Bw35 and prognosis in adult Still\u2019s disease. Arthritis Rheum. 1981;24:1469\u201372. https:\/\/doi.org\/10.1002\/art.1780241203.","journal-title":"Arthritis Rheum"},{"key":"1993_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/art.1780290316","volume":"29","author":"JMGW Wouters","year":"1986","unstructured":"Wouters JMGW, Reekers P, van de Putte LBA. Adult-onset still\u2019s disease. Disease course and HLA associations. Arthritis Rheum. 1986;29:415\u20138. https:\/\/doi.org\/10.1002\/art.1780290316.","journal-title":"Arthritis Rheum"},{"key":"1993_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","volume":"40","author":"T Fujii","year":"2001","unstructured":"Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still\u2019s disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398\u2013404. https:\/\/doi.org\/10.1093\/rheumatology\/40.12.1398.","journal-title":"Rheumatology (Oxford)"},{"key":"1993_CR18","unstructured":"Joung CI, Lee HS, Lee SW, et al. Association between HLA-DR B1 and clinical features of adult onset Still\u2019s disease in Korea. Clin Exp Rheumatol. 2003;21:489\u201392. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12942703."},{"key":"1993_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12016-019-08747-8","volume":"58","author":"S Li","year":"2020","unstructured":"Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still\u2019s disease. Clin Rev Allergy Immunol. 2020;58:71\u201381. https:\/\/doi.org\/10.1007\/s12016-019-08747-8.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1993_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81:406\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220578.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR21","unstructured":"Kim JJ, Kim J-K, Shim S-C, et al. MEFV gene mutations and their clinical significance in Korean patients with adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2013;31:60\u20133. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24064016."},{"key":"1993_CR22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00296-012-2609-8","volume":"33","author":"F Cosan","year":"2013","unstructured":"Cosan F, Emrence Z, Erbag G, et al. The association of TNFRSF1A gene and MEFV gene mutations with adult onset Still\u2019s disease. Rheumatol Int. 2013;33:1675\u201380. https:\/\/doi.org\/10.1007\/s00296-012-2609-8.","journal-title":"Rheumatol Int"},{"key":"1993_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.131563","volume":"41","author":"E Garcia-Melchor","year":"2014","unstructured":"Garcia-Melchor E, Grados D, Gonz\u00e1lez-Roca E, et al. CIAS1 and NOD2 genes in adult-onset Still\u2019s disease. J Rheumatol. 2014;41:1566\u20137. https:\/\/doi.org\/10.3899\/jrheum.131563.","journal-title":"J Rheumatol"},{"key":"1993_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00296-017-3885-0","volume":"38","author":"R Sighart","year":"2018","unstructured":"Sighart R, Rech J, Hueber A, et al. Evidence for genetic overlap between adult onset Still\u2019s disease and hereditary periodic fever syndromes. Rheumatol Int. 2018;38:111\u201320. https:\/\/doi.org\/10.1007\/s00296-017-3885-0.","journal-title":"Rheumatol Int"},{"key":"1993_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/art.38877","volume":"67","author":"SM Wakil","year":"2015","unstructured":"Wakil SM, Monies DM, Abouelhoda M, et al. Association of a mutation in LACC1 With a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2015;67:288\u201395. https:\/\/doi.org\/10.1002\/art.38877.","journal-title":"Arthritis Rheumatol"},{"key":"1993_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/cei\/uxac014","volume":"208","author":"P Ruscitti","year":"2022","unstructured":"Ruscitti P, Berardicurti O, Di Cola I, et al. The hyper-expression of NLRP4 characterizes the occurrence of macrophage activation syndrome assessing STING pathway in adult-onset Still\u2019s disease. Clin Exp Immunol. 2022;208:95\u2013102. https:\/\/doi.org\/10.1093\/cei\/uxac014.","journal-title":"Clin Exp Immunol"},{"key":"1993_CR27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/sj.gene.6363922","volume":"3","author":"T Sugiura","year":"2002","unstructured":"Sugiura T, Kawaguchi Y, Harigai M, et al. Association between adult-onset Still\u2019s disease and interleukin-18 gene polymorphisms. Genes Immun. 2002;3:394\u20139. https:\/\/doi.org\/10.1038\/sj.gene.6363922.","journal-title":"Genes Immun"},{"key":"1993_CR28","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3899\/jrheum.090316","volume":"36","author":"D-Y Chen","year":"2009","unstructured":"Chen D-Y, Chen Y-M, Chen H-H, et al. Functional association of interleukin 18 gene -607 (C\/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still\u2019s disease. J Rheumatol. 2009;36:2284\u20139. https:\/\/doi.org\/10.3899\/jrheum.090316.","journal-title":"J Rheumatol"},{"key":"1993_CR29","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar4239","volume":"15","author":"F-F Wang","year":"2013","unstructured":"Wang F-F, Huang X-F, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still\u2019s disease. Arthritis Res Ther. 2013;15:R65. https:\/\/doi.org\/10.1186\/ar4239.","journal-title":"Arthritis Res Ther"},{"key":"1993_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/life11050382","volume":"11","author":"W-T Hung","year":"2021","unstructured":"Hung W-T, Chen Y-M, Hung S-I, et al. CARD8 SNP rs11672725 Identified as a potential genetic variant for adult-onset Still\u2019s disease. Life. 2021;11:382. https:\/\/doi.org\/10.3390\/life11050382.","journal-title":"Life"},{"key":"1993_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/genes12060904","volume":"12","author":"W-T Hung","year":"2021","unstructured":"Hung W-T, Hung S-I, Chen Y-M, et al. The association of ATG16L1 variations with clinical phenotypes of adult-onset Still\u2019s disease. Genes (Basel). 2021;12:904. https:\/\/doi.org\/10.3390\/genes12060904.","journal-title":"Genes (Basel)"},{"key":"1993_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/art.41635","volume":"73","author":"M Wang","year":"2021","unstructured":"Wang M, Liu M, Jia J, et al. Association of the leukocyte immunoglobulin-like receptor A3 gene with neutrophil activation and disease susceptibility in adult-onset Still\u2019s disease. Arthritis Rheumatol. 2021;73:1033\u201343. https:\/\/doi.org\/10.1002\/art.41635.","journal-title":"Arthritis Rheumatol"},{"key":"1993_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8640719","volume":"2020","author":"Y-M Chen","year":"2020","unstructured":"Chen Y-M, Hung W-T, Chang W-C, et al. Genetic association and expression correlation between colony-stimulating factor 1 gene encoding M-CSF and adult-onset Still\u2019s disease. J Immunol Res. 2020;2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/8640719.","journal-title":"J Immunol Res"},{"key":"1993_CR34","unstructured":"Uziel Y, Pomeranz A, Brik R, et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J Rheumatol. 1999;26(5):1187\u20139."},{"key":"1993_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semarthrit.2012.05.003","volume":"42","author":"JY-Y Lee","year":"2012","unstructured":"Lee JY-Y, Hsu C-K, Liu M-F, et al. Evanescent and persistent pruritic eruptions of adult-onset Still disease: a clinical and pathologic study of 36 patients. Semin Arthritis Rheum. 2012;42:317\u201326. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.05.003.","journal-title":"Semin Arthritis Rheum"},{"key":"1993_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.881431","author":"S Rao","year":"2022","unstructured":"Rao S, Tsang LS-L, Zhao M, et al. Adult-onset Still\u2019s disease: a disease at the crossroad of innate immunity and autoimmunity. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.881431.","journal-title":"Front Med"},{"key":"1993_CR37","doi-asserted-by":"publisher","first-page":"13038","DOI":"10.3390\/ijms222313038","volume":"22","author":"J-W Kim","year":"2021","unstructured":"Kim J-W, Ahn M-H, Jung J-Y, et al. An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Int J Mol Sci. 2021;22:13038. https:\/\/doi.org\/10.3390\/ijms222313038.","journal-title":"Int J Mol Sci"},{"key":"1993_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-018-1800-z","volume":"21","author":"Q Hu","year":"2019","unstructured":"Hu Q, Shi H, Zeng T, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still\u2019s disease. Arthritis Res Ther. 2019;21:9. https:\/\/doi.org\/10.1186\/s13075-018-1800-z.","journal-title":"Arthritis Res Ther"},{"key":"1993_CR39","unstructured":"Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol. 2003;30(11):2422\u20137."},{"key":"1993_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/03008200903461462","volume":"51","author":"D-Y Chen","year":"2010","unstructured":"Chen D-Y, Chen Y-M, Chen H-H, et al. The associations of circulating CD4 + CD25 high regulatory T cells and TGF-\u03b2 with disease activity and clinical course in patients with adult-onset Still\u2019s disease. Connect Tissue Res. 2010;51:370\u20137. https:\/\/doi.org\/10.3109\/03008200903461462.","journal-title":"Connect Tissue Res"},{"key":"1993_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967\u201374. https:\/\/doi.org\/10.1038\/ni1488.","journal-title":"Nat Immunol"},{"key":"1993_CR42","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.42137","volume":"74","author":"BA Binstadt","year":"2022","unstructured":"Binstadt BA, Nigrovic PA. The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2022;74:1122\u201331. https:\/\/doi.org\/10.1002\/art.42137.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"1993_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3899\/jrheum.220128","volume":"50","author":"Y Ito","year":"2023","unstructured":"Ito Y, Nakahara H, Nakajima A. Development of pulmonary alveolar proteinosis in a patient with adult-onset Still disease treated with tocilizumab. J Rheumatol. 2023;50:288\u20139. https:\/\/doi.org\/10.3899\/jrheum.220128.","journal-title":"J Rheumatol"},{"key":"1993_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105654","author":"S Bindoli","year":"2023","unstructured":"Bindoli S, Lococo S, Calabrese F, et al. Pulmonary alveolar proteinosis in an adult patient affected by Still\u2019s disease and recurrent episodes of macrophage activation syndrome. Jt Bone Spine. 2023. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105654.","journal-title":"Jt Bone Spine"},{"key":"1993_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S290329","volume":"16","author":"P Galozzi","year":"2022","unstructured":"Galozzi P, Bindoli S, Doria A, et al. Progress in biological therapies for adult-onset Still\u2019s disease. Biol Targets Ther. 2022;16:21\u201334. https:\/\/doi.org\/10.2147\/BTT.S290329.","journal-title":"Biol Targets Ther"},{"key":"1993_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220928964","author":"S Bindoli","year":"2020","unstructured":"Bindoli S, Felicetti M, Sfriso P, et al. The amount of cytokine-release defines different shades of Sars-Cov2 infection. Exp Biol Med Published Online First. 2020. https:\/\/doi.org\/10.1177\/1535370220928964.","journal-title":"Exp Biol Med Published Online First"},{"key":"1993_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0.","journal-title":"Lancet"},{"key":"1993_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02573-9","author":"F Perrone","year":"2020","unstructured":"Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020. https:\/\/doi.org\/10.1186\/s12967-020-02573-9.","journal-title":"J Transl Med"},{"key":"1993_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105524","volume":"90","author":"S Bindoli","year":"2023","unstructured":"Bindoli S, Galozzi P, Doria A, et al. Intravenous anakinra to curb cytokine storm in adult-onset Still\u2019s disease and in macrophage activation syndrome: a case series. Jt bone spine. 2023;90: 105524. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105524.","journal-title":"Jt bone spine"},{"key":"1993_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome. Crit Care Med. 2016;44:275\u201381. https:\/\/doi.org\/10.1097\/CCM.0000000000001402.","journal-title":"Crit Care Med"},{"key":"1993_CR51","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0140-6736(87)90204-2","volume":"329","author":"T Ota","year":"1987","unstructured":"Ota T, Higashi S, Suzuki H, et al. Increased serum ferritin levels in adult Still\u2019s disease. Lancet. 1987;329:562\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(87)90204-2.","journal-title":"Lancet"},{"key":"1993_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.autrev.2007.01.016","volume":"6","author":"G Zandman-Goddard","year":"2007","unstructured":"Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6:457\u201363. https:\/\/doi.org\/10.1016\/j.autrev.2007.01.016.","journal-title":"Autoimmun Rev"},{"key":"1993_CR53","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/imj.12002","volume":"42","author":"NK Loh","year":"2012","unstructured":"Loh NK, Lucas M, Fernandez S, et al. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J. 2012;42:1358\u201362. https:\/\/doi.org\/10.1111\/imj.12002.","journal-title":"Intern Med J"},{"key":"1993_CR54","unstructured":"Colafrancesco S, Priori R, Alessandri C, et al. The hyperferritinemic syndromes and CD163: a marker of macrophage activation. Isr Med Assoc J. 2014;16:662\u20133. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25438465."},{"key":"1993_CR55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2021.09.023","volume":"67","author":"K Kaushal","year":"2022","unstructured":"Kaushal K, Kaur H, Sarma P, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022;67:172\u201381. https:\/\/doi.org\/10.1016\/j.jcrc.2021.09.023.","journal-title":"J Crit Care"},{"key":"1993_CR56","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol. 2018;14:603\u201318. https:\/\/doi.org\/10.1038\/s41584-018-0081-x.","journal-title":"Nat Rev Rheumatol"},{"key":"1993_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","volume":"61","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53\u201362. https:\/\/doi.org\/10.1007\/s12026-014-8561-9.","journal-title":"Immunol Res"},{"key":"1993_CR58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","volume":"85","author":"S Mitrovic","year":"2018","unstructured":"Mitrovic S, Fautrel B. New markers for adult-onset Still\u2019s disease. Jt Bone Spine. 2018;85:285\u201393. https:\/\/doi.org\/10.1016\/j.jbspin.2017.05.011.","journal-title":"Jt Bone Spine"},{"key":"1993_CR59","unstructured":"Fautrel B, Le Mo\u00ebl G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease. J Rheumatol. 2001;28(2):322\u20139."},{"key":"1993_CR60","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029970","volume":"101","author":"K Daghor Abbaci","year":"2022","unstructured":"Daghor Abbaci K, Ait Hamadouche N, Otmani F, et al. Validation of the neutrophil-to-lymphocyte ratio as a new simple biomarker of adult onset Still\u2019s disease: a STROBE-compliant prospective observational study. Medicine (Baltimore). 2022;101: e29970. https:\/\/doi.org\/10.1097\/MD.0000000000029970.","journal-title":"Medicine (Baltimore)"},{"key":"1993_CR61","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/ijms17081342","volume":"17","author":"H-A Kim","year":"2016","unstructured":"Kim H-A, Han J, Kim W-J, et al. TLR4 Endogenous ligand S100A8\/A9 levels in adult-onset Still\u2019s disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17:1342. https:\/\/doi.org\/10.3390\/ijms17081342.","journal-title":"Int J Mol Sci"},{"key":"1993_CR62","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3899\/jrheum.091120","volume":"37","author":"S-Y Jung","year":"2010","unstructured":"Jung S-Y, Park Y-B, Ha Y-J, et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still\u2019s disease. J Rheumatol. 2010;37:1029\u201334. https:\/\/doi.org\/10.3899\/jrheum.091120.","journal-title":"J Rheumatol"},{"key":"1993_CR63","doi-asserted-by":"publisher","first-page":"13320","DOI":"10.3390\/ijms222413320","volume":"22","author":"B Maranini","year":"2021","unstructured":"Maranini B, Ciancio G, Govoni M. Adult-onset Still\u2019s disease: novel biomarkers of specific subsets, disease activity, and relapsing forms. Int J Mol Sci. 2021;22:13320. https:\/\/doi.org\/10.3390\/ijms222413320.","journal-title":"Int J Mol Sci"},{"key":"1993_CR64","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3899\/jrheum.170020","volume":"44","author":"JH Han","year":"2017","unstructured":"Han JH, Suh C-H, Jung J-Y, et al. Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset Still\u2019s disease. J Rheumatol. 2017;44:740\u20137. https:\/\/doi.org\/10.3899\/jrheum.170020.","journal-title":"J Rheumatol"},{"key":"1993_CR65","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.3390\/ijms241311125","volume":"24","author":"C Baggio","year":"2023","unstructured":"Baggio C, Bindoli S, Guidea I, et al. IL-18 in Autoinflammatory diseases: focus on adult onset Still disease and macrophages activation syndrome. Int J Mol Sci. 2023;24:11125. https:\/\/doi.org\/10.3390\/ijms241311125.","journal-title":"Int J Mol Sci"},{"key":"1993_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750114","author":"T Shiga","year":"2021","unstructured":"Shiga T, Nozaki Y, Tomita D, et al. Usefulness of interleukin-18 as a diagnostic biomarker to differentiate adult-onset Still\u2019s disease with\/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.750114.","journal-title":"Front Immunol"},{"key":"1993_CR67","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3899\/jrheum.130575","volume":"41","author":"R Priori","year":"2014","unstructured":"Priori R, Colafrancesco S, Alessandri C, et al. Interleukin 18: a biomarker for differential diagnosis between adult-onset Still\u2019s disease and sepsis. J Rheumatol. 2014;41:1118\u201323. https:\/\/doi.org\/10.3899\/jrheum.130575.","journal-title":"J Rheumatol"},{"key":"1993_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719544","author":"P-K Chen","year":"2021","unstructured":"Chen P-K, Lan J-L, Huang P-H, et al. Interleukin-18 is a potential biomarker to discriminate active adult-onset Still\u2019s disease from COVID-19. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.719544.","journal-title":"Front Immunol"},{"key":"1993_CR69","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1038\/s41598-019-44032-6","volume":"9","author":"H-A Kim","year":"2019","unstructured":"Kim H-A, Kim YH, Jeon YK, et al. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8\/A9 in lymph nodes of patients with adult-onset Still\u2019s disease. Sci Rep. 2019;9:7517. https:\/\/doi.org\/10.1038\/s41598-019-44032-6.","journal-title":"Sci Rep"},{"key":"1993_CR70","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/rheumatology\/keaa368","volume":"60","author":"J Jia","year":"2021","unstructured":"Jia J, Yang L, Cao Z, et al. Neutrophil-derived lipocalin-2 in adult-onset Still\u2019s disease: a novel biomarker of disease activity and liver damage. Rheumatology. 2021;60:304\u201315. https:\/\/doi.org\/10.1093\/rheumatology\/keaa368.","journal-title":"Rheumatology"},{"key":"1993_CR71","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1093\/rheumatology\/keaa135","volume":"59","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chi H, Sun Y, et al. Serum sTREM-1 in adult-onset Still\u2019s disease: a novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology. 2020;59:3293\u2013302. https:\/\/doi.org\/10.1093\/rheumatology\/keaa135.","journal-title":"Rheumatology"},{"key":"1993_CR72","doi-asserted-by":"publisher","first-page":"10240","DOI":"10.1038\/s41598-022-14004-4","volume":"12","author":"JH Han","year":"2022","unstructured":"Han JH, Ahn M-H, Jung J-Y, et al. Elevated expression of TLR2 and its correlation with disease activity and clinical manifestations in adult-onset Still\u2019s disease. Sci Rep. 2022;12:10240. https:\/\/doi.org\/10.1038\/s41598-022-14004-4.","journal-title":"Sci Rep"},{"key":"1993_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12891-015-0569-3","volume":"16","author":"D-Y Chen","year":"2015","unstructured":"Chen D-Y, Chen Y-M, Lin C-C, et al. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still\u2019s disease. BMC Musculoskelet Disord. 2015;16:111. https:\/\/doi.org\/10.1186\/s12891-015-0569-3.","journal-title":"BMC Musculoskelet Disord"},{"key":"1993_CR74","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1038\/s41598-017-04086-w","volume":"7","author":"T-L Liao","year":"2017","unstructured":"Liao T-L, Chen Y-M, Hsieh C-W, et al. Upregulation of circulating microRNA-134 in adult-onset Still\u2019s disease and its use as potential biomarker. Sci Rep. 2017;7:4214. https:\/\/doi.org\/10.1038\/s41598-017-04086-w.","journal-title":"Sci Rep"},{"key":"1993_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03099","author":"Q Hu","year":"2019","unstructured":"Hu Q, Gong W, Gu J, et al. Plasma microRNA profiles as a potential biomarker in differentiating adult-onset Still\u2019s disease from sepsis. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2018.03099.","journal-title":"Front Immunol"},{"key":"1993_CR76","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10067-015-2922-1","volume":"34","author":"Y Kamiya","year":"2015","unstructured":"Kamiya Y, Kawada J, Kawano Y, et al. Serum microRNAs as potential biomarkers of juvenile idiopathic arthritis. Clin Rheumatol. 2015;34:1705\u201312. https:\/\/doi.org\/10.1007\/s10067-015-2922-1.","journal-title":"Clin Rheumatol"},{"key":"1993_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.544412","author":"S Bindoli","year":"2020","unstructured":"Bindoli S, Galozzi P, Magnani F, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography with magnetic resonance for diagnosing adult-onset Still\u2019s disease. Front Med. 2020. https:\/\/doi.org\/10.3389\/fmed.2020.544412.","journal-title":"Front Med"},{"key":"1993_CR78","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015123","volume":"98","author":"P Ruscitti","year":"2019","unstructured":"Ruscitti P, Cipriani P, Liakouli V, et al. Managing adult-onset Still\u2019s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore). 2019;98: e15123. https:\/\/doi.org\/10.1097\/MD.0000000000015123.","journal-title":"Medicine (Baltimore)"},{"key":"1993_CR79","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/030097400447624","volume":"29","author":"R Koizumi","year":"2000","unstructured":"Koizumi R, Yoshito Tsukada H. Treatment of adult Still\u2019s disease with dexamethasone, an alternative to prednisolone. Scand J Rheumatol. 2000;29:396\u20138. https:\/\/doi.org\/10.1080\/030097400447624.","journal-title":"Scand J Rheumatol"},{"key":"1993_CR80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0172","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne AC, Aric\u00f2 M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002. https:\/\/doi.org\/10.1182\/blood-2002-01-0172.","journal-title":"Blood"},{"key":"1993_CR81","unstructured":"Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still\u2019s disease. J Rheumatol. 1999;26(2):373\u20138."},{"key":"1993_CR82","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12098-019-02912-9","volume":"86","author":"P Pal","year":"2019","unstructured":"Pal P, Giri PP, Sinha R. Cyclosporine in resistant systemic arthritis\u2014a cheaper alternative to biologics. Indian J Pediatr. 2019;86:590\u20134. https:\/\/doi.org\/10.1007\/s12098-019-02912-9.","journal-title":"Indian J Pediatr"},{"key":"1993_CR83","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354. https:\/\/doi.org\/10.1136\/ard.2010.134254.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR84","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008\u201311. https:\/\/doi.org\/10.3899\/jrheum.111549.","journal-title":"J Rheumatol"},{"key":"1993_CR85","doi-asserted-by":"publisher","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","volume":"58","author":"SJ Vastert","year":"2019","unstructured":"Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still\u2019s disease. Rheumatology. 2019;58:vi9-22. https:\/\/doi.org\/10.1093\/rheumatology\/kez350.","journal-title":"Rheumatology"},{"key":"1993_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","volume":"39","author":"R Giacomelli","year":"2021","unstructured":"Giacomelli R, Sota J, Ruscitti P, et al. The treatment of adult-onset Still\u2019s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clin Exp Rheumatol. 2021;39:187\u201395. https:\/\/doi.org\/10.55563\/clinexprheumatol\/fsq5vq.","journal-title":"Clin Exp Rheumatol"},{"key":"1993_CR87","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2147\/DDDT.S73428","volume":"8","author":"D Hong","year":"2014","unstructured":"Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345\u201357. https:\/\/doi.org\/10.2147\/DDDT.S73428.","journal-title":"Drug Des Devel Ther"},{"key":"1993_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152139","volume":"58","author":"B Fautrel","year":"2023","unstructured":"Fautrel B, Patterson J, Bowe C, et al. Systematic review on the use of biologics in adult-onset still\u2019s disease. Semin Arthritis Rheum. 2023;58: 152139. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152139.","journal-title":"Semin Arthritis Rheum"},{"key":"1993_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial\u2217. Crit Care Med Published Online First. 2016. https:\/\/doi.org\/10.1097\/CCM.0000000000001402.","journal-title":"Crit Care Med Published Online First"},{"key":"1993_CR90","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"key":"1993_CR91","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","volume":"73","author":"P Quartier","year":"2021","unstructured":"Quartier P, Alexeeva E, Constantin T, et al. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb\/IV open-label, randomized study. Arthritis Rheumatol. 2021;73:336\u201346. https:\/\/doi.org\/10.1002\/art.41488.","journal-title":"Arthritis Rheumatol"},{"key":"1993_CR92","unstructured":"Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 2018;36(4):668\u201375."},{"key":"1993_CR93","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","volume":"79","author":"C Kedor","year":"2020","unstructured":"Kedor C, Listing J, Zernicke J, et al. Canakinumab for treatment of adult-onset Still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79:1090\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217155.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR94","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.semarthrit.2021.08.007","volume":"51","author":"JM Cota-Arce","year":"2021","unstructured":"Cota-Arce JM, Cota J, De Le\u00f3n-Nava MA, et al. Efficacy and safety of canakinumab in the treatment of adult-onset Still\u2019s disease: a systematic review. Semin Arthritis Rheum. 2021;51:1282\u201390. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.007.","journal-title":"Semin Arthritis Rheum"},{"key":"1993_CR95","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66:2570\u20139. https:\/\/doi.org\/10.1002\/art.38699.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"1993_CR96","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486\u201396. https:\/\/doi.org\/10.1002\/art.38042.","journal-title":"Arthritis Rheum"},{"key":"1993_CR97","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","volume":"71","author":"O Petryna","year":"2012","unstructured":"Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still\u2019s disease. Ann Rheum Dis. 2012;71:2056\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201409.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR98","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"key":"1993_CR99","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1093\/rheumatology\/keab047","volume":"60","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021;60:4568\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/keab047.","journal-title":"Rheumatology"},{"key":"1993_CR100","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","volume":"28","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis. Mod Rheumatol. 2018;28:849\u201357. https:\/\/doi.org\/10.1080\/14397595.2017.1416924.","journal-title":"Mod Rheumatol"},{"key":"1993_CR101","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77:1720\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR102","unstructured":"Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still\u2019s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 2016;34(6 Suppl 102):S64\u201371."},{"key":"1993_CR103","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10067-021-05921-2","volume":"41","author":"K-T Tang","year":"2022","unstructured":"Tang K-T, Hsieh C-W, Chen H-H, et al. The effectiveness of tocilizumab in treating refractory adult-onset Still\u2019s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clin Rheumatol. 2022;41:557\u201366. https:\/\/doi.org\/10.1007\/s10067-021-05921-2.","journal-title":"Clin Rheumatol"},{"key":"1993_CR104","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/rheumatology\/kez154","volume":"58","author":"SR Simeni Njonnou","year":"2019","unstructured":"Simeni Njonnou SR, Soyfoo MS, Vandergheynst F-A. Efficacy of sarilumab in adult-onset Still\u2019s disease as a corticosteroid-sparing agent. Rheumatology. 2019;58:1878\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kez154.","journal-title":"Rheumatology"},{"key":"1993_CR105","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207818.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR106","unstructured":"Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still\u2019s disease refractory to conventional therapy. Clin Exp Rheumatol 2001;19:329\u201332. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11407090."},{"key":"1993_CR107","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262\u20136. https:\/\/doi.org\/10.1136\/ard.2004.024026.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR108","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/rheumatology\/keab726","volume":"61","author":"S Mitrovic","year":"2022","unstructured":"Mitrovic S, Hassold N, Kamissoko A, et al. Adult-onset Still\u2019s disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift? Rheumatology. 2022;61:2535\u201347. https:\/\/doi.org\/10.1093\/rheumatology\/keab726.","journal-title":"Rheumatology"},{"key":"1993_CR109","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard.2005.047621","volume":"65","author":"K Ahmadi-Simab","year":"2006","unstructured":"Ahmadi-Simab K. Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Ann Rheum Dis. 2006;65:1117\u20138. https:\/\/doi.org\/10.1136\/ard.2005.047621.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR110","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4081\/reumatismo.2016.888","volume":"68","author":"N Belfeki","year":"2016","unstructured":"Belfeki N, Smiti Khanfir M, Said F, et al. Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Reumatismo. 2016;68:159\u201362. https:\/\/doi.org\/10.4081\/reumatismo.2016.888.","journal-title":"Reumatismo"},{"key":"1993_CR111","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","volume":"17","author":"RA Ostrowski","year":"2011","unstructured":"Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset Still disease successfully treated with abatacept. JCR J Clin Rheumatol. 2011;17:315\u20137. https:\/\/doi.org\/10.1097\/RHU.0b013e31822c53ad.","journal-title":"JCR J Clin Rheumatol"},{"key":"1993_CR112","unstructured":"Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still\u2019s disease. Clin Exp Rheumatol 2010;28(2):265\u20137."},{"key":"1993_CR113","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0248-8663(96)80703-X","volume":"16","author":"S Permal","year":"1995","unstructured":"Permal S, Wechsler B, Cabane J, et al. Traitement de la maladie de Still de l\u2019adulte par immunoglobulines intraveineuses. La Rev M\u00e9decine Interne. 1995;16:250\u20134. https:\/\/doi.org\/10.1016\/0248-8663(96)80703-X.","journal-title":"La Rev M\u00e9decine Interne"},{"key":"1993_CR114","unstructured":"Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still\u2019s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998;16(3):295\u20138."},{"key":"1993_CR115","unstructured":"Uziel Y, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol. 1996;23(5):910\u20138."},{"key":"1993_CR116","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.55563\/clinexprheumatol\/1o41c8","volume":"40","author":"V Myachikova","year":"2022","unstructured":"Myachikova V, Moiseeva O, Konradi A, et al. A retrospective analysis of colchicine in combination with NSAIDs therapy in patients with systemic form of adult-onset Still\u2019s disease with serositis. Clin Exp Rheumatol. 2022;40:1474\u20139. https:\/\/doi.org\/10.55563\/clinexprheumatol\/1o41c8.","journal-title":"Clin Exp Rheumatol"},{"key":"1993_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.930071","author":"Z Boyadzhieva","year":"2022","unstructured":"Boyadzhieva Z, Ruffer N, Burmester G, et al. Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: a systematic review. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.930071.","journal-title":"Front Med"},{"key":"1993_CR118","doi-asserted-by":"publisher","first-page":"1412.2","DOI":"10.1136\/annrheumdis-2021-eular.2210","volume":"80","author":"L Gillard","year":"2021","unstructured":"Gillard L, Mitrovic S, Reumaux H, et al. AB0772 JAK inhibitors in refractory adult and childhood onset Still\u2019s disease. Ann Rheum Dis. 2021;80:1412.2-1413. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2210.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR119","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu Q, Wang M, Jia J, et al. Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79:842\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216699.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR120","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001246","volume":"6","author":"M Kacar","year":"2020","unstructured":"Kacar M, Fitton J, Gough AK, et al. Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease. RMD Open. 2020;6: e001246. https:\/\/doi.org\/10.1136\/rmdopen-2020-001246.","journal-title":"RMD Open"},{"key":"1993_CR121","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40268-023-00417-7","volume":"23","author":"Z Sun","year":"2023","unstructured":"Sun Z, Li R, Wang Y, et al. Efficacy of baricitinib in patients with refractory adult-onset Still\u2019s disease. Drugs R D. 2023;23:109\u201320. https:\/\/doi.org\/10.1007\/s40268-023-00417-7.","journal-title":"Drugs R D"},{"key":"1993_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, Novick D, Kim S, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013. https:\/\/doi.org\/10.3389\/fimmu.2013.00289.","journal-title":"Front Immunol"},{"key":"1993_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212608","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis. 2018. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212608.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR124","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/annrheumdis-2018-214496","volume":"79","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Kiefer D, Braun J, et al. Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease. Ann Rheum Dis. 2020;79:e10\u2013e10. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214496.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR125","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, de Graaf K, Pires Marafon D, et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209020.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR126","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82:857\u201365. https:\/\/doi.org\/10.1136\/ard-2022-223739.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR127","doi-asserted-by":"publisher","first-page":"887","DOI":"10.21037\/atm-20-3127","volume":"8","author":"JB Gabr","year":"2020","unstructured":"Gabr JB, Liu E, Mian S, et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still\u2019s disease: case report and review of the literature. Ann Transl Med. 2020;8:887\u2013887. https:\/\/doi.org\/10.21037\/atm-20-3127.","journal-title":"Ann Transl Med."},{"key":"1993_CR128","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cei\/uxad065","volume":"213","author":"AD Hakim","year":"2023","unstructured":"Hakim AD, Awili M, O\u2019Neal HR, et al. Efficacy and safety of MAS825 (anti-IL-1\u03b2\/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function. Clin Exp Immunol. 2023;213:265\u201375. https:\/\/doi.org\/10.1093\/cei\/uxad065.","journal-title":"Clin Exp Immunol"},{"key":"1993_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115587","volume":"167","author":"D-H Kim","year":"2023","unstructured":"Kim D-H, Lee K-J, Park J, et al. Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease. Biomed Pharmacother. 2023;167: 115587. https:\/\/doi.org\/10.1016\/j.biopha.2023.115587.","journal-title":"Biomed Pharmacother"},{"key":"1993_CR130","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kl\u00fcck","year":"2020","unstructured":"Kl\u00fcck V, Jansen TLTA, Janssen M, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2:e270\u201380. https:\/\/doi.org\/10.1016\/S2665-9913(20)30065-5.","journal-title":"Lancet Rheumatol"},{"key":"1993_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107358","volume":"92","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lv Q, Zheng M, et al. NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol. 2021;92: 107358. https:\/\/doi.org\/10.1016\/j.intimp.2020.107358.","journal-title":"Int Immunopharmacol"},{"key":"1993_CR132","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AAB, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248\u201355. https:\/\/doi.org\/10.1038\/nm.3806.","journal-title":"Nat Med"},{"key":"1993_CR133","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214:3219\u201338. https:\/\/doi.org\/10.1084\/jem.20171419.","journal-title":"J Exp Med"},{"key":"1993_CR134","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/neup.12802","volume":"42","author":"H Jia","year":"2022","unstructured":"Jia H, Qi X, Fu L, et al. <scp>NLRP3<\/scp> inflammasome inhibitor ameliorates ischemic stroke by reprogramming the phenotype of microglia\/macrophage in a murine model of distal middle cerebral artery occlusion. Neuropathology. 2022;42:181\u20139. https:\/\/doi.org\/10.1111\/neup.12802.","journal-title":"Neuropathology"},{"key":"1993_CR135","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/08923973.2021.1925293","volume":"43","author":"A Saeedi-Boroujeni","year":"2021","unstructured":"Saeedi-Boroujeni A, Mahmoudian-Sani M-R, Nashibi R, et al. Tranilast: a potential anti-inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol Immunotoxicol. 2021;43:247\u201358. https:\/\/doi.org\/10.1080\/08923973.2021.1925293.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1993_CR136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40268-015-0102-z","volume":"15","author":"BA Owona","year":"2015","unstructured":"Owona BA, Schluesener HJ. Molecular insight in the multifunctional effects of oridonin. Drugs R D. 2015;15:233\u201344. https:\/\/doi.org\/10.1007\/s40268-015-0102-z.","journal-title":"Drugs R D"},{"key":"1993_CR137","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12011-019-01865-6","volume":"195","author":"AA Fouad","year":"2020","unstructured":"Fouad AA, Abdel-Aziz AM, Hamouda AAH. Diacerein downregulates NLRP3\/Caspase-1\/IL-1\u03b2 and IL-6\/STAT3 pathways of inflammation and apoptosis in a rat model of cadmium testicular toxicity. Biol Trace Elem Res. 2020;195:499\u2013505. https:\/\/doi.org\/10.1007\/s12011-019-01865-6.","journal-title":"Biol Trace Elem Res"},{"key":"1993_CR138","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","volume":"321","author":"W Wannamaker","year":"2007","unstructured":"Wannamaker W, Davies R, Namchuk M, et al. ( S )-1-(( S )-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S )-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspa. J Pharmacol Exp Ther. 2007;321:509\u201316. https:\/\/doi.org\/10.1124\/jpet.106.111344.","journal-title":"J Pharmacol Exp Ther"},{"key":"1993_CR139","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/cr.2015.139","volume":"25","author":"W He","year":"2015","unstructured":"He W, Wan H, Hu L, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion. Cell Res. 2015;25:1285\u201398. https:\/\/doi.org\/10.1038\/cr.2015.139.","journal-title":"Cell Res"},{"key":"1993_CR140","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736\u201345. https:\/\/doi.org\/10.1038\/s41590-020-0669-6.","journal-title":"Nat Immunol"},{"key":"1993_CR141","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/art.40420","volume":"70","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a fully human granulocyte\u2013macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody. Arthritis Rheumatol. 2018;70:679\u201389. https:\/\/doi.org\/10.1002\/art.40420.","journal-title":"Arthritis Rheumatol"},{"key":"1993_CR142","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/art.40323","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase <scp>II<\/scp> b study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:49\u201359. https:\/\/doi.org\/10.1002\/art.40323.","journal-title":"Arthritis Rheumatol"},{"key":"1993_CR143","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","volume":"74","author":"F Behrens","year":"2015","unstructured":"Behrens F, Tak PP, \u00d8stergaard M, et al. MOR103, a human monoclonal antibody to granulocyte\u2013macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015;74:1058\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204816.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR144","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","volume":"2","author":"G De Luca","year":"2020","unstructured":"De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2:e465\u201373. https:\/\/doi.org\/10.1016\/S2665-9913(20)30170-3.","journal-title":"Lancet Rheumatol"},{"key":"1993_CR145","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","volume":"35","author":"P Sfriso","year":"2016","unstructured":"Sfriso P, Priori R, Valesini G, et al. Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683\u20139. https:\/\/doi.org\/10.1007\/s10067-016-3308-8.","journal-title":"Clin Rheumatol"},{"key":"1993_CR146","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.semarthrit.2020.01.005","volume":"50","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Tomelleri A, Sartorelli S, et al. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum. 2020;50:509\u201314. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.005.","journal-title":"Semin Arthritis Rheum"},{"key":"1993_CR147","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19. https:\/\/doi.org\/10.1186\/s13023-015-0228-7.","journal-title":"Orphanet J Rare Dis"},{"key":"1993_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076034","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9 T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis Published Online First. 2008. https:\/\/doi.org\/10.1136\/ard.2007.076034.","journal-title":"Ann Rheum Dis Published Online First"},{"key":"1993_CR149","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/ar3366","volume":"13","author":"K Laskari","year":"2011","unstructured":"Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study. Arthritis Res Ther. 2011;13:R91. https:\/\/doi.org\/10.1186\/ar3366.","journal-title":"Arthritis Res Ther"},{"key":"1993_CR150","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822\u20136. https:\/\/doi.org\/10.1002\/acr.21901.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1993_CR151","unstructured":"Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still\u2019s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31(1):47\u201352."},{"key":"1993_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1838-6","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther Published Online First. 2019. https:\/\/doi.org\/10.1186\/s13075-019-1838-6.","journal-title":"Arthritis Res Ther Published Online First"},{"key":"1993_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00369","author":"S Colafrancesco","year":"2017","unstructured":"Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still\u2019s disease: a multicentre retrospective observational study. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/fphar.2017.00369.","journal-title":"Front Pharmacol"},{"key":"1993_CR154","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B. Tumour necrosis factor blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262\u20136. https:\/\/doi.org\/10.1136\/ard.2004.024026.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR155","doi-asserted-by":"publisher","first-page":"1759720X2093313","DOI":"10.1177\/1759720X20933133","volume":"12","author":"P Ruscitti","year":"2020","unstructured":"Ruscitti P, Ursini F, Sota J, et al. The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still\u2019s disease A systematic review and meta-analysis of observational studies. Ther Adv Musculoskelet Dis. 2020;12:1759720X2093313. https:\/\/doi.org\/10.1177\/1759720X20933133.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1993_CR156","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/ard.56.2.144","volume":"56","author":"T Fujii","year":"1997","unstructured":"Fujii T, Akizuki M, Kameda H, et al. Methotrexate treatment in patients with adult onset Still\u2019s disease\u2013-retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56:144\u20138. https:\/\/doi.org\/10.1136\/ard.56.2.144.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR157","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10165-008-0126-0","volume":"19","author":"M Mitamura","year":"2009","unstructured":"Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still\u2019s disease. Mod Rheumatol. 2009;19:57\u201363. https:\/\/doi.org\/10.1007\/s10165-008-0126-0.","journal-title":"Mod Rheumatol"},{"key":"1993_CR158","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum. 2010;62:2530\u20135. https:\/\/doi.org\/10.1002\/art.27532.","journal-title":"Arthritis Rheum"},{"key":"1993_CR159","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00296-013-2765-5","volume":"34","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Hot A, Huissoud C, et al. Adult-onset Still\u2019s disease and pregnancy: about ten cases and review of the literature. Rheumatol Int. 2014;34:867\u201371. https:\/\/doi.org\/10.1007\/s00296-013-2765-5.","journal-title":"Rheumatol Int"},{"key":"1993_CR160","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.4049\/jimmunol.2300065","volume":"210","author":"M Harel","year":"2023","unstructured":"Harel M, Fauteux-Daniel S, Rodriguez E, et al. IL-18 binding protein\u2013producing cells attenuate anemia in murine macrophage activation syndrome. J Immunol. 2023;210:1790\u2013803. https:\/\/doi.org\/10.4049\/jimmunol.2300065.","journal-title":"J Immunol"},{"key":"1993_CR161","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2845","author":"Z Huang","year":"2019","unstructured":"Huang Z, Lee PY, Yao X, et al. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2018-2845.","journal-title":"Pediatrics"},{"key":"1993_CR162","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/art.30238","volume":"63","author":"J Vojinovic","year":"2011","unstructured":"Vojinovic J, Damjanov N, D\u2019Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:1452\u20138. https:\/\/doi.org\/10.1002\/art.30238.","journal-title":"Arthritis Rheum"},{"key":"1993_CR163","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","volume":"81","author":"B Bader-Meunier","year":"2022","unstructured":"Bader-Meunier B, Hadchouel A, Berteloot L, et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease\u202f: a case report. Ann Rheum Dis. 2022;81:e20\u2013e20. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216983.","journal-title":"Ann Rheum Dis"},{"key":"1993_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111442","volume":"138","author":"Q-L Chen","year":"2021","unstructured":"Chen Q-L, Yin H-R, He Q-Y, et al. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother. 2021;138: 111442. https:\/\/doi.org\/10.1016\/j.biopha.2021.111442.","journal-title":"Biomed Pharmacother"},{"key":"1993_CR165","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijmm.2023.5238","volume":"51","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang Z, Zheng Y, et al. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). Int J Mol Med. 2023;51:35. https:\/\/doi.org\/10.3892\/ijmm.2023.5238.","journal-title":"Int J Mol Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-01993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-01993-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-01993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T14:07:02Z","timestamp":1711894022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-01993-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":165,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-01993-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Padova within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"We have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SB carried out the search strategy, retrieved the literature and wrote the manuscript; CB prepared the figure, wrote the manuscript and revised it; AD revised the manuscript; and PS revised and drafted the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}